Keith MS - Search Results

1

Economic and Humanistic Burden of Dry Eye Disease in Europe, North America, and Asia: A Systematic Literature Review.

McDonald M, Patel DA, Keith MS, Snedecor SJ. McDonald M, et al. Among authors: keith ms. Ocul Surf. 2016 Apr;14(2):144-67. doi: 10.1016/j.jtos.2015.11.002. Epub 2015 Dec 28. Ocul Surf. 2016. PMID: 26733111 Free article. Review.

2

Associations between signs and symptoms of dry eye disease: a systematic review.

Bartlett JD, Keith MS, Sudharshan L, Snedecor SJ. Bartlett JD, et al. Among authors: keith ms. Clin Ophthalmol. 2015 Sep 16;9:1719-30. doi: 10.2147/OPTH.S89700. eCollection 2015. Clin Ophthalmol. 2015. PMID: 26396495 Free PMC article. Review.

3

Cost-minimization analysis of lanthanum carbonate versus sevelamer hydrochloride in US patients with end-stage renal disease.

Keith MS, Wilson RJ, Preston P, Copley JB. Keith MS, et al. Clin Ther. 2014 Sep 1;36(9):1276-86. doi: 10.1016/j.clinthera.2014.06.036. Epub 2014 Jul 26. Clin Ther. 2014. PMID: 25069799 Free article. Clinical Trial.

4

Real-world dose-relativity, tablet burden, and cost comparison of conversion between sevelamer hydrochloride/carbonate and lanthanum carbonate monotherapies.

Keith MS, Sibbel S, Copley JB, Wilson RJ, Brunelli SM. Keith MS, et al. Clin Ther. 2014 Oct 1;36(10):1431-42.e1. doi: 10.1016/j.clinthera.2014.07.012. Epub 2014 Aug 20. Clin Ther. 2014. PMID: 25150194 Free article.

5

Global prevalence and economic and humanistic burden of astigmatism in cataract patients: a systematic literature review.

Anderson DF, Dhariwal M, Bouchet C, Keith MS. Anderson DF, et al. Among authors: keith ms. Clin Ophthalmol. 2018 Mar 6;12:439-452. doi: 10.2147/OPTH.S146829. eCollection 2018. Clin Ophthalmol. 2018. PMID: 29563768 Free PMC article. Review.

6

Lanthanum carbonate oral powder: satisfaction, preference and adherence in French and Spanish patients with end-stage renal disease.

Keith M, de Sequera P, Clair F, Pedersini R. Keith M, et al. Drugs Context. 2016 Oct 14;5:212300. doi: 10.7573/dic.212300. eCollection 2016. Drugs Context. 2016. PMID: 27803726 Free PMC article.

7

Analysis of serum phosphate control and phosphate binder utilization in incident hemodialysis patients.

Farrand KF, Copley JB, Heise J, Fridman M, Keith MS, Poole L. Farrand KF, et al. Among authors: keith ms. Int J Nephrol Renovasc Dis. 2014 Jul 5;7:261-9. doi: 10.2147/IJNRD.S58037. eCollection 2014. Int J Nephrol Renovasc Dis. 2014. PMID: 25045277 Free PMC article.

8

Cost-effectiveness of lanthanum carbonate in the treatment of hyperphosphatemia in dialysis patients: a Canadian payer perspective.

Vegter S, Tolley K, Keith MS, Lok CE, Soroka SD, Morton AR. Vegter S, et al. Among authors: keith ms. Clin Ther. 2012 Jul;34(7):1531-43. doi: 10.1016/j.clinthera.2012.06.006. Epub 2012 Jun 27. Clin Ther. 2012. PMID: 22742885

9

Cost-effectiveness of lanthanum carbonate in the treatment of hyperphosphatemia in chronic kidney disease before and during dialysis.

Vegter S, Tolley K, Keith MS, Postma MJ. Vegter S, et al. Among authors: keith ms. Value Health. 2011 Sep-Oct;14(6):852-8. doi: 10.1016/j.jval.2011.05.005. Epub 2011 Jun 23. Value Health. 2011. PMID: 21914505

10

Cost-effectiveness of lanthanum carbonate versus sevelamer hydrochloride for the treatment of hyperphosphatemia in patients with end-stage renal disease: a US payer perspective.

Park H, Rascati KL, Keith MS, Hodgkins P, Smyth M, Goldsmith D, Akehurst R. Park H, et al. Among authors: keith ms. Value Health. 2011 Dec;14(8):1002-9. doi: 10.1016/j.jval.2011.05.043. Epub 2011 Jul 28. Value Health. 2011. PMID: 22152168

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results